644 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
3 Biotech Stocks With a Lot to Prove at ASH 2019 https://www.fool.com/investing/2019/12/02/3-biotech-stocks-with-a-lot-to-prove-at-ash-2019.aspx?source=iedfolrf0000001 Dec 02, 2019 - These companies have some important presentations scheduled for the last big oncology conference of the year.
Top Research Reports for Merck, Eli Lilly & Charter Communications http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-ZC-FT-research_daily-643445 Nov 27, 2019 - Top Research Reports for Merck, Eli Lilly & Charter Communications
Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug http://www.zacks.com/stock/news/629205/alkermes-submits-nda-to-fda-for-schizophrenia-bipolar-i-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-629205 Nov 20, 2019 - Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes http://www.zacks.com/stock/news/619673/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-619673 Nov 14, 2019 - Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales http://www.zacks.com/stock/news/610314/corcept-cort-earnings-beat-in-q3-korlym-boosts-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-610314 Nov 08, 2019 - Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-ZC-FT-analyst_blog|earnings_article-606644 Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Value Biotech ETFs & Stocks to Buy Now http://www.zacks.com/stock/news/602866/value-biotech-etfs-stocks-to-buy-now?cid=CS-ZC-FT-etf_news_and_commentary-602866 Nov 04, 2019 - Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
What's in the Cards for Teva (TEVA) This Earnings Season? http://www.zacks.com/stock/news/602734/whats-in-the-cards-for-teva-teva-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-602734 Nov 04, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales http://www.zacks.com/stock/news/596377/sanofi-sny-q3-earnings-beat-vaccines-chc-units-hurt-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-596377 Oct 31, 2019 - Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.

Pages: 123456...65

Page 1>